Eli Lilly has built a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron, as disclosed in its 2025 annual report published in February 2026. 1 3 4 The stockpile aims to prevent shortages like those experienced with injectable GLP-1RAs Mounjaro and Zepbound in 2022, resolved by late 2024. 1 Orforglipron is under FDA review with a decision expected in April 2026, expedited by a Commissioner's National Priority Review Voucher. 1 This inventory marks an increase from $550 million in February 2025 and reflects confidence in approval and high demand. 1 4 5 Novo Nordisk's oral Wegovy was approved in December 2025 and launched in January 2026, with strong early sales including 50,000 prescriptions by end of January. 1 Lilly is investing $27 billion in new US manufacturing facilities, including for orforglipron production. 1 Sources: 1. https://www.pharmaceutical-technology.com/news/eli-lilly-builds-orforglipron-cache-to-avoid-previous-glp-1ra-shor...
- Get link
- X
- Other Apps